Continuous IV Infusion of MESNA Can Prevent Hemorrhagic Cystitis in HSCT and Retain MESNA Concentration in Urine
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Role of Natural Antioxidants in Cancer.
Alsulami F, Shaheed S Cancer Treat Res. 2024; 191:95-117.
PMID: 39133405 DOI: 10.1007/978-3-031-55622-7_4.
Canadian Urological Association Best Practice Report: Pediatric hemorrhagic cystitis.
Hannick J, Koyle M Can Urol Assoc J. 2019; 13(11):E325-E334.
PMID: 31763977 PMC: 6877374. DOI: 10.5489/cuaj.5993.
References
1.
Haselberger M, Schwinghammer T
. Efficacy of mesna for prevention of hemorrhagic cystitis after high-dose cyclophosphamide therapy. Ann Pharmacother. 1995; 29(9):918-21.
DOI: 10.1177/106002809502900914.
View
2.
Takamoto S, Sakura N, Yashiki M, Kojima T
. Inactivation of acrolein by sodium 2-mercaptoethanesulfonate using headspace-solid-phase microextraction gas chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2003; 791(1-2):365-9.
DOI: 10.1016/s1570-0232(03)00259-9.
View
3.
Lima M, Ferreira F, Macedo F, Brito G, Ribeiro R
. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis. Cancer Chemother Pharmacol. 2006; 59(5):643-50.
DOI: 10.1007/s00280-006-0307-5.
View
4.
Giraud G, Bogdanovic G, Priftakis P, Remberger M, Svahn B, Barkholt L
. The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. Haematologica. 2006; 91(3):401-4.
View
5.
Korkmaz A, Topal T, Oter S
. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol. 2007; 23(5):303-12.
DOI: 10.1007/s10565-006-0078-0.
View